Vendor Intelligence Report: GLP Keep Body Peptide

Published 13 Jun 2026. 20-page investigative report on who is behind GLP Keep Body Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 9 Finnrick lab tests, GLP Keep Body shows 6 pass / 2 fail — overall pass rate 67%. The tested catalog is narrow, covering only tirzepatide and retatrutide, and the signal is uneven rather than uniformly bad. Retatrutide is the cleaner observed line; tirzepatide is the line with documented failures, with ratings losing margin under stricter grading.

The vendor's identity story is the bigger diligence problem. GLP Keep Body claims a seven-year biotechnology history, but web and registry records place the hard public trail in late 2025, with China-linked registration data and no public corporate match under the vendor name in the searched registries. A vendor-displayed tirzepatide COA also points outside the brand, carrying a client field tied to a separate botanicals business and personnel trail.

The sales channel adds supply-chain opacity. A named contact on GLP Keep Body's own page matches an external Chinese factory-direct peptide seller handle; that does not make China sourcing disqualifying, but it does raise the stakes for lot matching, current-batch COA verification, and independent testing. The site further leans on fabricated social proof: six researcher testimonials use stock photos and unverifiable elite-institution credentials while product pages make human-benefit claims under a research-use posture.

Inside the full report:

  • Appendix A — Finnrick Laboratory Data with per-product pass/fail rates and methodology-divergence charts for both tested products
  • WHOIS, DNS, certificate, Cloudflare-token, and source-code infrastructure captures
  • Delaware and OpenCorporates registry searches tested against the seven-year company-history claim
  • COA provenance analysis for the tirzepatide certificate and outside client-email trail
  • Contact-page versus social-handle comparison for the factory-direct sales-channel finding
  • Testimonial stock-photo review and FDA comparator analysis of consumer-use peptide claims

Risk assessment

  • Misleading corporate-identity risk — high: The site claims 7+ years / biotech credibility, but glpkeepbody.com was created Oct 19, 2025 with CN registrant data and no Delaware or OpenCorporates entity was located.
  • Factory-direct supply-chain verification risk — high: GLP's own contact page lists Lydia / @Lydia1646, and external posts tie the same handle to Chinese factory-direct peptide sales; no verified US manufacturing or inventory was found.
  • Tirzepatide quality reliability risk — high: Tirzepatide is the weak tested line: 5 Finnrick tests, 3 pass / 2 fail, 74.98% current rating; retatrutide performed better and is not included in this risk row.
  • Fabricated social-proof and consumer-use marketing risk — high: All six captured testimonials use stock photos / unverifiable credentials, and product pages make weight-loss and fat-burning claims despite research-use positioning.
  • Beneficial-control and operator-history risk — medium: A vendor COA links john@diversifiedbotanics.com; public records tie John Ramsay to Diversified Botanics and prior FDA / CBD litigation history, but GLP ownership is not confirmed by filing.